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Abstract: Regulatory T (Treg) cells are considered to inhibit the
development of both type 1 (Th1) and type 2 helper T (Th2) cells.
However, it is recently reported that there are reduced numbers of Treg
cells in patients with allergic diseases as compared with individuals
who have high levels of serum immunoglobulin E and blood
eosinophils but are asymptomatic. Therefore, Treg cells may suppress
the onset of allergic disease by down-regulating other types of immune
cells besides Th1 and Th2 cells. The newly discovered interleukin
17Yproducing helper T cells that are responsible for autoimmune
inflammatory diseases may counteract Treg cells even in allergic diseases.
The Th2 cells that are capable of producing of high levels of tumor necrosis
factor-> may also be involved in inflammation in allergic diseases. In this
review, we further discuss the role of Th1, Th2, interleukin 17Yproducing
helper T cells, and Treg cells in allergic diseases by using the balancing
square model and the factors differentiating between patients with clinical
manifestations of allergic symptomatic and atopic individuals who are
sensitized but asymptomatic.
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Th1/Th2 PARADIGM THEORIZING FOR ALLERGIC
DISEASES IS ON THE RISE
There is an inverse correlation between the levels of
endotoxin in house dust and the incidence of atopic sensitiza-
tion and hay fever.1 The major role of endotoxin is considered
to be the stimulation of macrophages/antigen-presenting cells
to produce interleukin 12 (IL-12), which triggers the develop-
ment of antigen-specific type 1 helper T (Th1) cells and inhibits
the development of type 2 helper T (Th2) cells. As such, the
hygiene hypothesis associated with an increasing prevalence of
allergic diseases has been theorized by the Th1/Th2 paradigm
2
since a long time.
Most epidemiological studies supporting the hygiene
hypothesis also indicate that the preventive effect on allergy of
an Bunhygienic^ environment surrounded by many microbial
components is limited to early childhood.1 According to the
classic Th1/Th2 paradigm theory, this could be typically
speculated as shown in Figure 1. A Th2-dominant immune
system develops in an individual when the immune system is
exposed to allergens without prior exposure to microbial
components such as endotoxin early in life. On the other hand,
the development of allergen (antigen)-specific Th1 cells is
triggered by simultaneous exposure to the antigen and
microbial components. After childhood, the proportion of
Th1/Th2 cells is not drastically altered by microbial exposure
because of a decrease in the number of naive helper T cells that
can react with common allergens.
The incidence of Th1-mediated autoimmune diseases is
known to have increased in the last half century in parallel with
the increase of Th2-mediated allergic diseases.
3 The classic
Th1/Th2 paradigm cannot be used to explain this point.
ROLES OF VARIOUS REGULATORY
T-CELL POPULATIONS
Several subsets of CD4+ cells are able to prevent immune
responses against self-antigens or allergens. These cells are
called regulatory T (Treg) cells. Because Treg cells inhibit both
Th1- and Th2-cell development in vitro, increases in the
incidence of Th1 diseases and Th2-mediated diseases are now
thought to be related to an insufficient development of Treg
cells. However, there is no evidence yet whether the Bhygienic^
environment with exposure to less microbial components
during early life affects the development of Treg cells.
Among the several subsets, naturally occurring Treg
(nTreg) cells have been well investigated. These cells originate
in the thymus, express the repertoire of CD4+CD25+ (mouse)
or CD4+CD25high (human) and the transcription factor
forkhead box protein P3 (Foxp3), and have a major role in
modulating the activity of self-reactive cells by inducing the
destruction of autoreactive T cells mainly via cell-to-cell
contactYdependent mechanisms.4 Therefore, nTreg cells are
considered to mainly have a preventive role in autoimmune
diseases.
In humans, a population of CD4+CD25high T cells
with regulatory function very similar to nTreg cells but
derived from peripheral memory CD4+CD25- T cells has
recently been described.5 They are called adaptive Treg
(aTreg) cells
6 or inducible Treg (iTreg) cells. One of iTreg-cell
types is the IL-10Yproducing type 1 Treg (Tr1) cells, whose
suppressive function has been well documented in allergy
and autoimmunity.7 The term BiTreg^ is often used for the
IL-10Yproducing Tr1, whereas the term aTreg is often used
as CD4+CD25high T cells derived from peripheral memory
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CD4+CD25- T cells. Therefore, in this review, we have used
the term aTreg as Foxp3
+ CD4+CD25high T cells as shown in
the recent review article written by Bacchetta et al.8 Never-
theless, all subsets of Treg cells require a cytokine,
transforming growth factor-A (TGF-A), for their develop-
ment. The IL-10 is also produced not only by Tr1 cells, but also
by various cell types including regulatory dendritic cells that
can induce aTreg.
9 As such, these 2 cytokines play an important
role in immune regulation.
Forkhead box protein P3 mutant mice develop an
intense multiorgan inflammatory response, including allergic
airway inflammation, striking hyperimmunoglobulinemia E,
eosinophilia, and dysregulated Th1 and Th2 cytokine produc-
tion.10,11 In humans, genetic defects in Foxp3 cause immune
dysregulation, polyendocrinopathy, and enteropathy, X-linked
(IPEX) syndrome.12 Most IPEX patients have food allergy and
atopic dermatitisYrelated symptoms immediately after birth. It
is thus suggested that Foxp3+ Treg cells play an important
role in regulating common allergic disorders and IPEX. The
number of Foxp3+ Treg cells is decreased in skin lesions in
patients with atopic dermatitis and in patients with
psoriasis.13
Although Foxp3 is transiently expressed by antigen-
activated helper T cells,14 only persistent and high-level Foxp3
expression is related to the immunosuppressive functions.
IL-17YPRODUCING HELPER T CELLS THAT
TRIGGERED THE MAJOR REVISION FOR
Th1/Th2 THEORY
A major role for the cytokine IL-17 has recently been
described in various murine models of immune-mediated
tissue injury, organ-specific autoimmunity, allergic disorders,
and microbial infections. Interestingly, interferon-F (IFN-F)
derived from Th1 cells often prevents the IL-17Ymediated
inflammation in mice with experimental autoimmune
FIGURE 1. Environment surrounded by microbial components is effective only during early childhood. Only Tn’s are present during
infancy. The Th2-dominant immune system will develop when the immune system is exposed to allergens without microbial
components such as endotoxin. Allergen-associated Th2 adjuvants such as prostaglandins may enhance Th2 development. On
the other hand, antigen/allergen-specific Th1 cells can develop by simultaneous exposure to antigen/allergen and microbial
components. After childhood, microbial exposure cannot drastically alter the proportion of Th1/Th2 balance because the proportion
of Tn is decreased. Tn indicates naive helper T cells.
FIGURE 2. The balancing square model. The 4 T-cell types
(Th1, Th2, Th17, and Treg) antagonize each other. The
Th1-promoting cytokine, IL-12, is inhibitory to Th2-cell
development, whereas the Th2-promoting cytokine, IL-4,
blocks Th1-cell development. The Th1-derived IFN-F blocks
Th17-cell development. The Treg inhibits the development of
both Th1 and Th2 cells by direct contact.
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diseases.15,16 AT-cell subpopulation that exclusively produces
IL-17 (Th17) is now credited for causing and sustaining tissue
damage. Human and mouse Th17 cells may require different
sets of cytokines for their development. Thus, the identification
of the Th17 cells triggered a shift in the immunologists’
perspectives regarding the basis of tissue damage or auto-
immune diseases, where for more than 20 years the role of Th1
cells was considered paramount.16
However, it has been recently revealed that the
expression of IL-17 in human CD4+ T cells may be completely
different from that in mice.17 Unlike mouse, human IL-6 and
IL-21 do not induce IL-17 expression in either naive or
effector T cells. The TGF-A inhibits human Th17-cell
development but promotes mouse Th17-cell development
when costimulated with IL-6.17 It should also be noted that
in human adult peripheral blood, a large proportion of helper
T cells can produce both IFN-F and IL-4. The proportion of
Th17 cells in peripheral blood CD4
+ cells are consistently
less than 1% in the peripheral blood of healthy individuals,
and slightly higher among CD4+ T cells derived from
patients with Crohn’s disease.18 Autologous Treg-cell clones
suppress Th1 or Th2 cells, but not Th17 cells.
18 Never-
theless, IL-6 inhibits the development of both human and
mouse Treg cells.
19
FIGURE 3. Onset of allergic diseases may be determined by the ratio of proinflammatory T-cell subsets (Th17 and iTh2) versus Treg
subsets. A, In patients with chronic allergic diseases, proinflammatory T-cell subsets, that is, Th17 cells and Th2 cells that are capable
of producing high levels of TNF-> (iTh2 cells) are upregulated. B, In asymptomatic atopic individuals, Th2 cells that are capable of
producing IL-10 (rTh2 cells) may be up-regulated, and Th17 cells may be inactivated.
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The key cytokine of Th17 cells, IL-17, is known to
induce the production of proinflammatory cytokines such as
tumor necrosis factor-> (TNF->), IL-1A, IL-6, and proin-
flammatory chemokines CXCL1, 2, and 8 by acting on various
cell types.20 In humans, sputum IL-17A messenger RNA
levels are significantly elevated in patients with asthma as
compared with healthy controls.21 Endogenous IL-17 con-
tributes to the development of allergen-induced airway
hyperresponsiveness, and there is also evidence that IL-17
stimulates the release of several cytokines with known
capacity for airway remodeling from cells normally residing
in the airways.22
With the discovery of Th17 and Treg populations, the
balancing square model is now needed to explain the
pathogenesis of various immunological diseases. It also
enables us to explain the epidemiological data demonstrating
an increase in allergic diseases (Fig. 2). According to this
model, we speculate that substantial amounts of plant
antigens, parasites, molds, viruses, and bacteria are required
for balancing the total immune system (Fig. 2). Autoimmune
diseases are now considered to be initiated by an up-regulation
of Th17 cells and a defect in nTreg cell function, whereas
peritumor tissues are strikingly infiltrated with Foxp3+ nTreg
cells implying that these cells impinge upon immune-mediated
rejection of the tumor.23
ROLE OF aTreg CELLS IN THE ONSET OF
ALLERGIC DISEASES
Allergic diseases are caused by uncontrolled Th2-based
immune responses to environmental antigens. It has been
demonstrated that healthy nonatopic subjects have detectable
IL-10Yproducing allergen-specific Tr1-like Treg cells, whereas
the proportion of these Treg cells are very low in symptomatic
allergic patients.24
Several studies suggest a possible defect and impaired
function of nTreg cells in the pathogenesis of immune
responses toward allergens. However, like studies on auto-
immune diseases, it is often difficult to distinguish the
overlapping phenotypic characteristics between Treg cells
and activated helper T cells.8
We recently demonstrated that symptomatic atopic
patients had a lower Foxp3+CD4+ ratio than asymptomatic
controls having similar levels of serum IFN-F, total
immunoglobulin E (IgE), and eosinophils. These results
suggest that circulating Foxp3+CD4+ cells regulate unknown
factor(s) affecting the onset of allergic diseases, which are
unrelated to these Th1/Th2 markers. Measurement of Foxp3
+
CD4+ cells has the potential to aid in evaluating the presence
of active inflammation, which cannot be evaluated by known
Th1- and Th2-related markers in patients with allergic
diseases.25
One of the many reasonable explanations for this
observation is considered as follows, that is, down-regulation
of Foxp3+ aTreg cells is often related to up-regulation of Th17
cells. In mice, IL-17 activates mast cells to release a
proinflammatory cytokine, TNF->, and thus can cause
neutrophilic inflammation.26 In humans, Th17 cells may
enhance allergic inflammation by stimulating the tissue
resident cells to release TNF->, and are proven to evoke
marked inflammation and airway remodeling. Using the
FIGURE 4. A model for development of allergic and autoimmune diseases in the absence of microbial components. Increased ratio
of proinflammatory cytokines (IL-17, TSLP, and IL-6) versus regulatory cytokines (IL-10 and TGF-A) may play a key role in
determining inflammatory allergic/autoimmune diseases versus asymptomatic individuals.
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balancing square model, the immunological features of
symptomatic allergic diseases may be illustrated as in
Figure 3A. Among Th2-cell subtypes, TNF->Yrich inflam-
matory Th2 (iTh2) cells may be developed by stimulation of
dendritic cells with Th2 adjuvants associated with allergens
or thymic stromal lymphopoietin (TSLP) often found in
inflammatory tissues in allergic diseases.27 Thus, iTh2 and
Th17 cells can be both up-regulated in symptomatic allergic
patients, where mast cells are also activated. On the other hand,
in asymptomatic controls having similar high levels of IgE and
eosinophils, both Th2 and aTreg cells may be up-regulated.
Because of Th17 cells, the levels of IFN-F may be kept at
considerably high levels. However, these patients are often
infected with viruses at the site of inflammatory tissues because
of down-regulation of classic Th1 cells
28 capable of producing
antiviral cytokine IFN->.
Among Th2 subsets, IL-10Yproducing Treg cells may
be up-regulated in asymptomatic atopic individuals. Mast
cells are therefore not activated, despite the presence of high
levels of IgE antibodies and constant exposure to common
allergens as shown in Figure 3B. Nevertheless, it will be
necessary to determine why some people do not have
marked mast cell activation even though they are sensitized
to multiple allergens.
The nTreg cells can suppress not only T cells, but also
natural killer cells, dendritic cell maturation, and antibody
production by B cells.29 Recently, mast cells and nTreg-derived
IL-9 are found indispensable in nTreg-mediated peripheral
tolerance to allograft transplantation in a mouse model.30
Pollen immunotherapy that is known to induce allergen-
specific aTreg or Tr1 cells inhibits seasonal increases in IL-9
protein expression and c-Kit+ mast cell infiltration in the nasal
mucosa during the pollen season.31 It is of particular interest to
investigate a further relationship between aTreg and mast cells
in future studies.
CONCLUSION
An atopic predisposition is acquired via up-regulation of
Th2 cells compared with IFN-FYproducing helper T cells (Th1
cells and Th17 cells) specific for each allergen as shown in
Figure 1. Numerous epidemiological studies indicate that
microbial components affect the balance between these T-cell
types.1 It should be noted, however, that most of the people
who acquired an atopic predisposition in a hygienic environ-
ment are still asymptomatic or having very mild symptoms.25
At present, we have no answer as to why some further develop
the clinical manifestations of allergic disease, whereas others
remain asymptomatic.
We have reported that active atopic patients had a lower
Foxp3+CD4+ ratio than asymptomatic controls having similar
levels of serum IFN-F, total IgE, and eosinophils,25 suggesting
that the development of clinical manifestations of allergic
diseases may be determined by the ratio of proinflammatory T-
cell subsets (Th17 and iTh2) versus Treg subsets. Increased
ratio of proinflammatory cytokines (IL-17, TSLP, and IL-6)
versus regulatory cytokines (IL-10 and TGF-A) in severe
allergic diseases8,19,20,27 would activate further the balance
shift and form a positive feedback loop in chronic inflamma-
tion (Fig. 4). Nevertheless, we will have to identify the factors
influencing the balance shift of proinflammatory and regula-
tory T cell population.
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